ANIX - Company ID 0000715446
The table below shows Anixa Biosciences Inc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $210.00K | $210.00K | - | $512.00K | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $5.07M | $6.40M | $4.77M | $6.70M | $6.19M | $4.38M |
| SG&A |
Anixa Biosciences Inc reported annual revenue of $210.00K for fiscal year 2024. That is up 0.0% from $210.00K in fiscal 2023. Over the 10 fiscal years shown, annual revenue declined from $388.85K (FY 2013) to $210.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.63M |
| $7.43M |
| $6.29M |
| $7.17M |
| $7.07M |
| $5.60M |
| Operating income | -$11.70M | -$13.83M | -$11.01M | -$13.88M | -$13.14M | -$9.98M |
| Income tax | - | - | - | - | - | - |
| Net income | -$10.93M | -$12.55M | -$9.81M | -$13.60M | -$12.95M | -$10.02M |
| EPS (diluted) | -$0.34 | -$0.39 | -$0.32 | $0.45 | - | - |